SlideShare une entreprise Scribd logo
1  sur  23
LLeber’seber’s
HHereditaryereditary –– inherited from mitochondrial DNAinherited from mitochondrial DNA
OOpticptic –– affects the eyeaffects the eye
NNeuropathyeuropathy –– disease/abnormality of nervousdisease/abnormality of nervous
systemsystem
 Maternally inherited disorderMaternally inherited disorder
characterized by degenerationcharacterized by degeneration
of the retinal ganglion cells (of the retinal ganglion cells (RGCsRGCs))
and atrophy of the optic nerveand atrophy of the optic nerve
 Mutations are in the mitochondrialMutations are in the mitochondrial
(not nuclear) genome(not nuclear) genome
 Usually begins between the ages of 25 and 35 (but canUsually begins between the ages of 25 and 35 (but can
occur at any age) and leads to legal blindnessoccur at any age) and leads to legal blindness
 More common in males than femalesMore common in males than females
 It was first described in 1871 by Theodore Leber andIt was first described in 1871 by Theodore Leber and
is the most common cause of optic atrophy.is the most common cause of optic atrophy.
 Inherited from mother to allInherited from mother to all
offspringsoffsprings
 Only the egg contributesOnly the egg contributes
mitochondria to the embryomitochondria to the embryo
 2 billion mitochondria are2 billion mitochondria are
made every secondmade every second
throughout a person’s lifethroughout a person’s life
 250 mitochondria on the250 mitochondria on the
average are found in a cellaverage are found in a cell
 Life span is around 100 days.Life span is around 100 days.
 Number varies from cell to cellNumber varies from cell to cell
 Circular strand of DNACircular strand of DNA
consisting of 16,569 nucleotideconsisting of 16,569 nucleotide
basesbases
 Contains 37 genesContains 37 genes
 2 Encode for rRNA and 22 for2 Encode for rRNA and 22 for
tRNAtRNA
 13 genes encode for proteins13 genes encode for proteins
required for the biochemicalrequired for the biochemical
reactions inreactions in
process that generates ATP highprocess that generates ATP high
energy moleculesenergy molecules
 The rest 74 proteins forThe rest 74 proteins for oxidativeoxidative
phosphorylationphosphorylation are encoded byare encoded by
nuclear DNAnuclear DNA
 HeteroplasmyHeteroplasmy
- Some of the mt DNA has mutations- Some of the mt DNA has mutations
some does notsome does not
- 15% of individuals with- 15% of individuals with LHONLHON areare
heteroplasmicheteroplasmic
- The rest are- The rest are homoplasmichomoplasmic
 HomoplasmyHomoplasmy
All of theAll of the mtDNAmtDNA has at least one ofhas at least one of
the three types of mutations forthe three types of mutations for
or no mutations at all!!or no mutations at all!!
 This determines the type of phenotypeThis determines the type of phenotype
and the risk transmission.and the risk transmission.
 There is also a mitochondrial disorderThere is also a mitochondrial disorder
known as LHON (Leber's Hereditaryknown as LHON (Leber's Hereditary
Optic Neuropathy) where theOptic Neuropathy) where the
mitochondrial DNA mutations whichmitochondrial DNA mutations which
causes the disease (acquired blindness)causes the disease (acquired blindness)
are homoplasmic - meaning that all of theare homoplasmic - meaning that all of the
mitochondria carry the defect. However,mitochondria carry the defect. However,
just because a person has one of thejust because a person has one of the
LHON mitochondrial DNA mutationsLHON mitochondrial DNA mutations
does not mean they will become blind,does not mean they will become blind,
only about 10% will. Confusing? You bet!only about 10% will. Confusing? You bet!
Phenotypic threshold effectPhenotypic threshold effect
in mtDNA mutatinsin mtDNA mutatins
 Associated with mtDNA heteroplasmyAssociated with mtDNA heteroplasmy
 Critical threshold in proportion of mutations inCritical threshold in proportion of mutations in
mtDNA must be exceeded before disease appearsmtDNA must be exceeded before disease appears
 This is normally about 90%This is normally about 90%
 BUT,BUT, LHONLHON is generally homoplasmicis generally homoplasmic
 Interestingly certainInterestingly certain homoplasmichomoplasmic mtDNAmtDNA
mutations do not expressmutations do not express LHONLHON phenotype atphenotype at
all!!!all!!!
 85% to 90% of cases of85% to 90% of cases of
LHONLHON are usually due toare usually due to
one of the threeone of the three mtDNAmtDNA
point mutationspoint mutations
 ND4 ND1ND4 ND1 andand ND6ND6 subunitsubunit
genes ofgenes of of theof the
oxidative phosphorylationoxidative phosphorylation
chain in mitochondria, whichchain in mitochondria, which
is theis the 11stst
stepstep of theof the
 The rate ofThe rate of mtDNAmtDNA mutationsmutations
is 10-times greater than inis 10-times greater than in
nuclear DNAnuclear DNA
Complex 1
Site effected by the
3 point
mutations
found in LEBERS
Causes of LHONCauses of LHON
 3 point mutations at these sites3 point mutations at these sites::
1)1) G11778AG11778A
50-60%50-60% LHON populationLHON population
Mutation is located at positionMutation is located at position
11778 change is G to A11778 change is G to A
2)2) T14484CT14484C
10%10% LHON populationLHON population
3)3) G3460AG3460A::
8-25%8-25% LHON populationLHON population
 These mutations decrease production ofThese mutations decrease production of
ATP resulting in cell dysfunction and cellATP resulting in cell dysfunction and cell
deathdeath
 Production ofProduction of ROSROS
Reactive oxygen speciesReactive oxygen species – byproduct– byproduct
of oxidative phosphorylationof oxidative phosphorylation
 Environmental factorsEnvironmental factors
 Not everyone with one of theseNot everyone with one of these
mutations will developmutations will develop LHONLHON
 AdditionalAdditional geneticgenetic oror environmentalenvironmental
factorsfactors play an important role toplay an important role to
development of central vision lossdevelopment of central vision loss
 Males with one of these mutations have aMales with one of these mutations have a 40% lifetime40% lifetime
riskrisk to develop symptomsto develop symptoms
 Females have aFemales have a 10% risk10% risk, although the actual risk, although the actual risk
varies slightly from mutation to mutationvaries slightly from mutation to mutation
 Those factors that can reduce the blood supply toThose factors that can reduce the blood supply to
the retina and optic nervethe retina and optic nerve
 They areThey are suspectsuspect to 'trigger' the vision loss in LHONto 'trigger' the vision loss in LHON
a.a. Heavy drinking or smokingHeavy drinking or smoking
b.b. Exposure to poisonous fumesExposure to poisonous fumes
such as carbon monoxidesuch as carbon monoxide
c.c. High levels of stressHigh levels of stress
d.d. Medications:Medications:
Ethambutol –Ethambutol – Rx for TBRx for TB
Chloramphenicol –Chloramphenicol – for conjunctivitisfor conjunctivitis
e.e. Many other known toxinsMany other known toxins
that may cause blindnessthat may cause blindness
11778
3460
14484
RGCRGC (retinal ganglial cells)(retinal ganglial cells)
 These cells depend onThese cells depend on
oxidative phosphorylation dueoxidative phosphorylation due
to their:to their:
 HugeHuge ATP demandATP demand
 Very sensitive to energyVery sensitive to energy
supply and mitochondriasupply and mitochondria
defectsdefects
 Limited regenerationLimited regeneration
abilitiesabilities
 END RESULTEND RESULT = Vision= Vision
damage from degenerationdamage from degeneration
of optic nerve due toof optic nerve due to
insufficient ATP supplyinsufficient ATP supply
 LHON is found inLHON is found in 80% of80% of
young men in theiryoung men in their
twentiestwenties
 Female carriers have 85 -Female carriers have 85 -
90% chance of staying90% chance of staying
healthyhealthy
 WhyWhy??
 X - chromosome markersX - chromosome markers
have been found whichhave been found which
may influence diseasemay influence disease
outcome in carriers, calledoutcome in carriers, called
protective factorsprotective factors
Asymptomatic until visual
blurring develops
Acute PhaseAcute Phase::
 Painless, acute onset of central vision lossPainless, acute onset of central vision loss
 Peripheral vision (seeing out of the corner of thePeripheral vision (seeing out of the corner of the
eye) remainseye) remains
 Loss of visual acuity/colorLoss of visual acuity/color
 Once symptoms appear in one eye, other eye affectedOnce symptoms appear in one eye, other eye affected
within few weekswithin few weeks
Sub acute Phase
Atrophy of optic disc =
 Cardiac conduction defectsCardiac conduction defects
 TremorsTremors
 Numbness or weakness in arms or legNumbness or weakness in arms or leg
 Loss of ankle reflexesLoss of ankle reflexes
 Symptoms vary by gender and type of mutationSymptoms vary by gender and type of mutation
presentpresent
— the most common mutation and usually
the most severe vision loss
— usually has the best long term
prognosis or outcome
— has an intermediate
presentation
 Molecular genetic blood test using polymeraseMolecular genetic blood test using polymerase
chain reaction (PCR) techniqueschain reaction (PCR) techniques
 The test is 100% accurate forThe test is 100% accurate for LHONLHON when visualwhen visual
loss has already occurredloss has already occurred
 Interestingly, significant number of individualsInterestingly, significant number of individuals
who are suspected to havewho are suspected to have LHONLHON do not havedo not have
one of the three primary mtDNAone of the three primary mtDNA LHONLHON
mutations.mutations.
 So farSo far no treatmentno treatment has beenhas been
proven effective in controlledproven effective in controlled
trials fortrials for LHONLHON
 BUTBUT……..……..
 IdebenoneIdebenone,, a synthetic analoguea synthetic analogue
ofof coenzymeQ10coenzymeQ10 has been studieshas been studies
in clinical trials in Canada,in clinical trials in Canada,
Germany and UKGermany and UK
 IdebenoneIdebenone is a strongis a strong antioxidantantioxidant
and may be the key to providingand may be the key to providing
stability to nerve cell, decreasingstability to nerve cell, decreasing
the likelihood of oxidative damagethe likelihood of oxidative damage
caused by free radicals releasedcaused by free radicals released
when cells are destroyed bywhen cells are destroyed by
chemical toxinschemical toxins
 Neutralize free radicalNeutralize free radical production byproduction by
neuronal cells with supplementation ofneuronal cells with supplementation of
antioxidantsantioxidants
 VitaminsVitamins
 Natural plant extractsNatural plant extracts
 Vitamin EVitamin E
 Co-enzyme QCo-enzyme Q
 Vitamin CVitamin C
 Vitamin AVitamin A
 Ginkgo bilobaGinkgo biloba
 CurcuminCurcumin
ConclusionConclusion
 Point mutations in complex 1 due playPoint mutations in complex 1 due play
a major role in causing Lebersa major role in causing Lebers
 Decreased production of ATPDecreased production of ATP
underlies cell dysfunction and cellunderlies cell dysfunction and cell
deathdeath
 Although there is no treatment at thisAlthough there is no treatment at this
time, family history along with genetictime, family history along with genetic
testing and healthy lifestyle may effecttesting and healthy lifestyle may effect
the outcome of this disease as withthe outcome of this disease as with
other disease such as Cancerother disease such as Cancer
ReferencesReferences
 http://www.ifond.org/lhon.php3http://www.ifond.org/lhon.php3
 http://brain.oxfordjournals.org/cgi/content/full/124/1/20http://brain.oxfordjournals.org/cgi/content/full/124/1/20
99
 http://jnnp.bmj.com/cgi/content/abstract/75/12/1731http://jnnp.bmj.com/cgi/content/abstract/75/12/1731
 http://www.pubmedcentral.nih.gov/articlerender.fcgi?http://www.pubmedcentral.nih.gov/articlerender.fcgi?
artid=1914692artid=1914692
 http://genome.wellcome.ac.uk/doc_WTD020740.htmlhttp://genome.wellcome.ac.uk/doc_WTD020740.html
 http://www.slh.wisc.edu/genetics/basics_disease.dothttp://www.slh.wisc.edu/genetics/basics_disease.dot
 Thompson & Thompson.Thompson & Thompson. Genetics in MedicineGenetics in Medicine..
Saunders: 2007Saunders: 2007

Contenu connexe

Tendances

Genetics of Mitochondrial disorders
Genetics of Mitochondrial disordersGenetics of Mitochondrial disorders
Genetics of Mitochondrial disorders
Pramod Krishnan
 
Mitochondrial encephalomyopathies(Neurology)
Mitochondrial encephalomyopathies(Neurology)Mitochondrial encephalomyopathies(Neurology)
Mitochondrial encephalomyopathies(Neurology)
Caroline Karunya
 
Neurofibromatosis
NeurofibromatosisNeurofibromatosis
Neurofibromatosis
asteinman
 

Tendances (20)

MITOCHONDRIAL DISORDER
MITOCHONDRIAL DISORDERMITOCHONDRIAL DISORDER
MITOCHONDRIAL DISORDER
 
Genetics of Mitochondrial disorders
Genetics of Mitochondrial disordersGenetics of Mitochondrial disorders
Genetics of Mitochondrial disorders
 
Mitochondrial Inheritance in Man
Mitochondrial Inheritance in ManMitochondrial Inheritance in Man
Mitochondrial Inheritance in Man
 
Cytogenetic analysis
Cytogenetic analysisCytogenetic analysis
Cytogenetic analysis
 
MELAS
MELASMELAS
MELAS
 
Retinitis pigmentosa ppt
Retinitis pigmentosa ppt Retinitis pigmentosa ppt
Retinitis pigmentosa ppt
 
Comparitive genomic hybridisation
Comparitive genomic hybridisationComparitive genomic hybridisation
Comparitive genomic hybridisation
 
Whole exome sequencing(wes)
Whole exome sequencing(wes)Whole exome sequencing(wes)
Whole exome sequencing(wes)
 
Genomic imprinting
Genomic imprinting Genomic imprinting
Genomic imprinting
 
Presentation on Fluorescence in-Situ Hybridization (FISH)
Presentation on Fluorescence in-Situ Hybridization (FISH)Presentation on Fluorescence in-Situ Hybridization (FISH)
Presentation on Fluorescence in-Situ Hybridization (FISH)
 
Genetic influences on obesity development
Genetic influences on obesity developmentGenetic influences on obesity development
Genetic influences on obesity development
 
Retinoblastoma
RetinoblastomaRetinoblastoma
Retinoblastoma
 
Mitochondrial encephalomyopathies(Neurology)
Mitochondrial encephalomyopathies(Neurology)Mitochondrial encephalomyopathies(Neurology)
Mitochondrial encephalomyopathies(Neurology)
 
Optic neuropathy
Optic neuropathyOptic neuropathy
Optic neuropathy
 
Macular cherry red spot
Macular cherry red spotMacular cherry red spot
Macular cherry red spot
 
Genomic imprinting
Genomic imprintingGenomic imprinting
Genomic imprinting
 
Neurofibromatosis
NeurofibromatosisNeurofibromatosis
Neurofibromatosis
 
Retinoblastoma
RetinoblastomaRetinoblastoma
Retinoblastoma
 
Mt DNA
Mt DNAMt DNA
Mt DNA
 
DNA damage and DNA repair
DNA damage and DNA repairDNA damage and DNA repair
DNA damage and DNA repair
 

Similaire à Leber hereditary optic neuropathy

Genetics in haematology2012
Genetics in haematology2012Genetics in haematology2012
Genetics in haematology2012
Amir Muhriz
 

Similaire à Leber hereditary optic neuropathy (20)

Sle
SleSle
Sle
 
Genetic Disorders
Genetic DisordersGenetic Disorders
Genetic Disorders
 
Genetics mutation by Sohail
Genetics mutation by SohailGenetics mutation by Sohail
Genetics mutation by Sohail
 
polymorphism
polymorphism polymorphism
polymorphism
 
Cytogenetics
Cytogenetics Cytogenetics
Cytogenetics
 
DISEASES OF GENETIC MUTATION, TREATMENTS(2).pptx
DISEASES OF GENETIC MUTATION, TREATMENTS(2).pptxDISEASES OF GENETIC MUTATION, TREATMENTS(2).pptx
DISEASES OF GENETIC MUTATION, TREATMENTS(2).pptx
 
Myeloproliferative disorders
Myeloproliferative disordersMyeloproliferative disorders
Myeloproliferative disorders
 
Genetic disorders
Genetic  disordersGenetic  disorders
Genetic disorders
 
Genetics in haematology2012
Genetics in haematology2012Genetics in haematology2012
Genetics in haematology2012
 
Histiocytosis in children
Histiocytosis in childrenHistiocytosis in children
Histiocytosis in children
 
Single Gene Disorder/ Mendalian Disorder - Shumaila Riaz
Single Gene Disorder/ Mendalian Disorder - Shumaila RiazSingle Gene Disorder/ Mendalian Disorder - Shumaila Riaz
Single Gene Disorder/ Mendalian Disorder - Shumaila Riaz
 
orca_share_media1637351181660_6867548610641918072.pdf
orca_share_media1637351181660_6867548610641918072.pdforca_share_media1637351181660_6867548610641918072.pdf
orca_share_media1637351181660_6867548610641918072.pdf
 
Different symptoms of lupus by Lupura
Different symptoms of lupus by LupuraDifferent symptoms of lupus by Lupura
Different symptoms of lupus by Lupura
 
Genetic Mutations
Genetic MutationsGenetic Mutations
Genetic Mutations
 
Dna,genetics and hardware
Dna,genetics and hardwareDna,genetics and hardware
Dna,genetics and hardware
 
Chromosomal abnormalities by firoz
Chromosomal abnormalities by firozChromosomal abnormalities by firoz
Chromosomal abnormalities by firoz
 
Genetic
GeneticGenetic
Genetic
 
multiple myloma.pptx
multiple myloma.pptxmultiple myloma.pptx
multiple myloma.pptx
 
17-heredity-beger-for-students.pdf
17-heredity-beger-for-students.pdf17-heredity-beger-for-students.pdf
17-heredity-beger-for-students.pdf
 
Genetic-HL
Genetic-HLGenetic-HL
Genetic-HL
 

Plus de Dr Ramesh Krishnan

Plus de Dr Ramesh Krishnan (20)

Diagnosis and management of Hyperkalemia
 Diagnosis and management of Hyperkalemia Diagnosis and management of Hyperkalemia
Diagnosis and management of Hyperkalemia
 
Abg ramesh
Abg rameshAbg ramesh
Abg ramesh
 
Ischemic heart disease
Ischemic heart disease Ischemic heart disease
Ischemic heart disease
 
Approach to management of Hyperkalemia
Approach to management of  HyperkalemiaApproach to management of  Hyperkalemia
Approach to management of Hyperkalemia
 
Anemia in ckd
Anemia in ckd Anemia in ckd
Anemia in ckd
 
Uti
UtiUti
Uti
 
Chronopharmacology
ChronopharmacologyChronopharmacology
Chronopharmacology
 
Betaadrenergicblockers 150412052808-conversion-gate01
Betaadrenergicblockers 150412052808-conversion-gate01Betaadrenergicblockers 150412052808-conversion-gate01
Betaadrenergicblockers 150412052808-conversion-gate01
 
Alphablockers 140105052831-phpapp02
Alphablockers 140105052831-phpapp02Alphablockers 140105052831-phpapp02
Alphablockers 140105052831-phpapp02
 
Anticholinergics drugs-Dr Ramesh Krishnan
Anticholinergics drugs-Dr Ramesh KrishnanAnticholinergics drugs-Dr Ramesh Krishnan
Anticholinergics drugs-Dr Ramesh Krishnan
 
6966901
69669016966901
6966901
 
Cholinergic ramesh
Cholinergic rameshCholinergic ramesh
Cholinergic ramesh
 
Myocardial infarction
Myocardial infarctionMyocardial infarction
Myocardial infarction
 
Pophyria
PophyriaPophyria
Pophyria
 
Porphyria r
Porphyria rPorphyria r
Porphyria r
 
Porphyria
PorphyriaPorphyria
Porphyria
 
Porphyria r (1)
Porphyria r (1)Porphyria r (1)
Porphyria r (1)
 
Shelly hyperlipidemia
Shelly hyperlipidemiaShelly hyperlipidemia
Shelly hyperlipidemia
 
Cvs 6
Cvs 6Cvs 6
Cvs 6
 
Fri t13 carl_fratter_3.15
Fri t13 carl_fratter_3.15Fri t13 carl_fratter_3.15
Fri t13 carl_fratter_3.15
 

Leber hereditary optic neuropathy

  • 1.
  • 2. LLeber’seber’s HHereditaryereditary –– inherited from mitochondrial DNAinherited from mitochondrial DNA OOpticptic –– affects the eyeaffects the eye NNeuropathyeuropathy –– disease/abnormality of nervousdisease/abnormality of nervous systemsystem
  • 3.  Maternally inherited disorderMaternally inherited disorder characterized by degenerationcharacterized by degeneration of the retinal ganglion cells (of the retinal ganglion cells (RGCsRGCs)) and atrophy of the optic nerveand atrophy of the optic nerve  Mutations are in the mitochondrialMutations are in the mitochondrial (not nuclear) genome(not nuclear) genome  Usually begins between the ages of 25 and 35 (but canUsually begins between the ages of 25 and 35 (but can occur at any age) and leads to legal blindnessoccur at any age) and leads to legal blindness  More common in males than femalesMore common in males than females  It was first described in 1871 by Theodore Leber andIt was first described in 1871 by Theodore Leber and is the most common cause of optic atrophy.is the most common cause of optic atrophy.
  • 4.  Inherited from mother to allInherited from mother to all offspringsoffsprings  Only the egg contributesOnly the egg contributes mitochondria to the embryomitochondria to the embryo  2 billion mitochondria are2 billion mitochondria are made every secondmade every second throughout a person’s lifethroughout a person’s life  250 mitochondria on the250 mitochondria on the average are found in a cellaverage are found in a cell  Life span is around 100 days.Life span is around 100 days.
  • 5.  Number varies from cell to cellNumber varies from cell to cell  Circular strand of DNACircular strand of DNA consisting of 16,569 nucleotideconsisting of 16,569 nucleotide basesbases  Contains 37 genesContains 37 genes  2 Encode for rRNA and 22 for2 Encode for rRNA and 22 for tRNAtRNA  13 genes encode for proteins13 genes encode for proteins required for the biochemicalrequired for the biochemical reactions inreactions in process that generates ATP highprocess that generates ATP high energy moleculesenergy molecules  The rest 74 proteins forThe rest 74 proteins for oxidativeoxidative phosphorylationphosphorylation are encoded byare encoded by nuclear DNAnuclear DNA
  • 6.  HeteroplasmyHeteroplasmy - Some of the mt DNA has mutations- Some of the mt DNA has mutations some does notsome does not - 15% of individuals with- 15% of individuals with LHONLHON areare heteroplasmicheteroplasmic - The rest are- The rest are homoplasmichomoplasmic  HomoplasmyHomoplasmy All of theAll of the mtDNAmtDNA has at least one ofhas at least one of the three types of mutations forthe three types of mutations for or no mutations at all!!or no mutations at all!!  This determines the type of phenotypeThis determines the type of phenotype and the risk transmission.and the risk transmission.
  • 7.  There is also a mitochondrial disorderThere is also a mitochondrial disorder known as LHON (Leber's Hereditaryknown as LHON (Leber's Hereditary Optic Neuropathy) where theOptic Neuropathy) where the mitochondrial DNA mutations whichmitochondrial DNA mutations which causes the disease (acquired blindness)causes the disease (acquired blindness) are homoplasmic - meaning that all of theare homoplasmic - meaning that all of the mitochondria carry the defect. However,mitochondria carry the defect. However, just because a person has one of thejust because a person has one of the LHON mitochondrial DNA mutationsLHON mitochondrial DNA mutations does not mean they will become blind,does not mean they will become blind, only about 10% will. Confusing? You bet!only about 10% will. Confusing? You bet!
  • 8. Phenotypic threshold effectPhenotypic threshold effect in mtDNA mutatinsin mtDNA mutatins  Associated with mtDNA heteroplasmyAssociated with mtDNA heteroplasmy  Critical threshold in proportion of mutations inCritical threshold in proportion of mutations in mtDNA must be exceeded before disease appearsmtDNA must be exceeded before disease appears  This is normally about 90%This is normally about 90%  BUT,BUT, LHONLHON is generally homoplasmicis generally homoplasmic  Interestingly certainInterestingly certain homoplasmichomoplasmic mtDNAmtDNA mutations do not expressmutations do not express LHONLHON phenotype atphenotype at all!!!all!!!
  • 9.  85% to 90% of cases of85% to 90% of cases of LHONLHON are usually due toare usually due to one of the threeone of the three mtDNAmtDNA point mutationspoint mutations  ND4 ND1ND4 ND1 andand ND6ND6 subunitsubunit genes ofgenes of of theof the oxidative phosphorylationoxidative phosphorylation chain in mitochondria, whichchain in mitochondria, which is theis the 11stst stepstep of theof the  The rate ofThe rate of mtDNAmtDNA mutationsmutations is 10-times greater than inis 10-times greater than in nuclear DNAnuclear DNA
  • 10. Complex 1 Site effected by the 3 point mutations found in LEBERS
  • 11. Causes of LHONCauses of LHON  3 point mutations at these sites3 point mutations at these sites:: 1)1) G11778AG11778A 50-60%50-60% LHON populationLHON population Mutation is located at positionMutation is located at position 11778 change is G to A11778 change is G to A 2)2) T14484CT14484C 10%10% LHON populationLHON population 3)3) G3460AG3460A:: 8-25%8-25% LHON populationLHON population  These mutations decrease production ofThese mutations decrease production of ATP resulting in cell dysfunction and cellATP resulting in cell dysfunction and cell deathdeath  Production ofProduction of ROSROS Reactive oxygen speciesReactive oxygen species – byproduct– byproduct of oxidative phosphorylationof oxidative phosphorylation  Environmental factorsEnvironmental factors
  • 12.  Not everyone with one of theseNot everyone with one of these mutations will developmutations will develop LHONLHON  AdditionalAdditional geneticgenetic oror environmentalenvironmental factorsfactors play an important role toplay an important role to development of central vision lossdevelopment of central vision loss  Males with one of these mutations have aMales with one of these mutations have a 40% lifetime40% lifetime riskrisk to develop symptomsto develop symptoms  Females have aFemales have a 10% risk10% risk, although the actual risk, although the actual risk varies slightly from mutation to mutationvaries slightly from mutation to mutation
  • 13.  Those factors that can reduce the blood supply toThose factors that can reduce the blood supply to the retina and optic nervethe retina and optic nerve  They areThey are suspectsuspect to 'trigger' the vision loss in LHONto 'trigger' the vision loss in LHON a.a. Heavy drinking or smokingHeavy drinking or smoking b.b. Exposure to poisonous fumesExposure to poisonous fumes such as carbon monoxidesuch as carbon monoxide c.c. High levels of stressHigh levels of stress d.d. Medications:Medications: Ethambutol –Ethambutol – Rx for TBRx for TB Chloramphenicol –Chloramphenicol – for conjunctivitisfor conjunctivitis e.e. Many other known toxinsMany other known toxins that may cause blindnessthat may cause blindness
  • 15. RGCRGC (retinal ganglial cells)(retinal ganglial cells)  These cells depend onThese cells depend on oxidative phosphorylation dueoxidative phosphorylation due to their:to their:  HugeHuge ATP demandATP demand  Very sensitive to energyVery sensitive to energy supply and mitochondriasupply and mitochondria defectsdefects  Limited regenerationLimited regeneration abilitiesabilities  END RESULTEND RESULT = Vision= Vision damage from degenerationdamage from degeneration of optic nerve due toof optic nerve due to insufficient ATP supplyinsufficient ATP supply
  • 16.  LHON is found inLHON is found in 80% of80% of young men in theiryoung men in their twentiestwenties  Female carriers have 85 -Female carriers have 85 - 90% chance of staying90% chance of staying healthyhealthy  WhyWhy??  X - chromosome markersX - chromosome markers have been found whichhave been found which may influence diseasemay influence disease outcome in carriers, calledoutcome in carriers, called protective factorsprotective factors
  • 17. Asymptomatic until visual blurring develops Acute PhaseAcute Phase::  Painless, acute onset of central vision lossPainless, acute onset of central vision loss  Peripheral vision (seeing out of the corner of thePeripheral vision (seeing out of the corner of the eye) remainseye) remains  Loss of visual acuity/colorLoss of visual acuity/color  Once symptoms appear in one eye, other eye affectedOnce symptoms appear in one eye, other eye affected within few weekswithin few weeks Sub acute Phase Atrophy of optic disc =
  • 18.  Cardiac conduction defectsCardiac conduction defects  TremorsTremors  Numbness or weakness in arms or legNumbness or weakness in arms or leg  Loss of ankle reflexesLoss of ankle reflexes  Symptoms vary by gender and type of mutationSymptoms vary by gender and type of mutation presentpresent — the most common mutation and usually the most severe vision loss — usually has the best long term prognosis or outcome — has an intermediate presentation
  • 19.  Molecular genetic blood test using polymeraseMolecular genetic blood test using polymerase chain reaction (PCR) techniqueschain reaction (PCR) techniques  The test is 100% accurate forThe test is 100% accurate for LHONLHON when visualwhen visual loss has already occurredloss has already occurred  Interestingly, significant number of individualsInterestingly, significant number of individuals who are suspected to havewho are suspected to have LHONLHON do not havedo not have one of the three primary mtDNAone of the three primary mtDNA LHONLHON mutations.mutations.
  • 20.  So farSo far no treatmentno treatment has beenhas been proven effective in controlledproven effective in controlled trials fortrials for LHONLHON  BUTBUT……..……..  IdebenoneIdebenone,, a synthetic analoguea synthetic analogue ofof coenzymeQ10coenzymeQ10 has been studieshas been studies in clinical trials in Canada,in clinical trials in Canada, Germany and UKGermany and UK  IdebenoneIdebenone is a strongis a strong antioxidantantioxidant and may be the key to providingand may be the key to providing stability to nerve cell, decreasingstability to nerve cell, decreasing the likelihood of oxidative damagethe likelihood of oxidative damage caused by free radicals releasedcaused by free radicals released when cells are destroyed bywhen cells are destroyed by chemical toxinschemical toxins
  • 21.  Neutralize free radicalNeutralize free radical production byproduction by neuronal cells with supplementation ofneuronal cells with supplementation of antioxidantsantioxidants  VitaminsVitamins  Natural plant extractsNatural plant extracts  Vitamin EVitamin E  Co-enzyme QCo-enzyme Q  Vitamin CVitamin C  Vitamin AVitamin A  Ginkgo bilobaGinkgo biloba  CurcuminCurcumin
  • 22. ConclusionConclusion  Point mutations in complex 1 due playPoint mutations in complex 1 due play a major role in causing Lebersa major role in causing Lebers  Decreased production of ATPDecreased production of ATP underlies cell dysfunction and cellunderlies cell dysfunction and cell deathdeath  Although there is no treatment at thisAlthough there is no treatment at this time, family history along with genetictime, family history along with genetic testing and healthy lifestyle may effecttesting and healthy lifestyle may effect the outcome of this disease as withthe outcome of this disease as with other disease such as Cancerother disease such as Cancer
  • 23. ReferencesReferences  http://www.ifond.org/lhon.php3http://www.ifond.org/lhon.php3  http://brain.oxfordjournals.org/cgi/content/full/124/1/20http://brain.oxfordjournals.org/cgi/content/full/124/1/20 99  http://jnnp.bmj.com/cgi/content/abstract/75/12/1731http://jnnp.bmj.com/cgi/content/abstract/75/12/1731  http://www.pubmedcentral.nih.gov/articlerender.fcgi?http://www.pubmedcentral.nih.gov/articlerender.fcgi? artid=1914692artid=1914692  http://genome.wellcome.ac.uk/doc_WTD020740.htmlhttp://genome.wellcome.ac.uk/doc_WTD020740.html  http://www.slh.wisc.edu/genetics/basics_disease.dothttp://www.slh.wisc.edu/genetics/basics_disease.dot  Thompson & Thompson.Thompson & Thompson. Genetics in MedicineGenetics in Medicine.. Saunders: 2007Saunders: 2007